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Abstract
Background: The parasitic protozoan Trypanosoma brucei utilizes glycolysis exclusively for ATP production during infection
of the mammalian host. The first step in this metabolic pathway is mediated by hexokinase (TbHK), an enzyme essential to
the parasite that transfers the c-phospho of ATP to a hexose. Here we describe the identification and confirmation of novel
small molecule inhibitors of bacterially expressed TbHK1, one of two TbHKs expressed by T. brucei, using a high throughput
screening assay.
Methodology/Principal Findings: Exploiting optimized high throughput screening assay procedures, we interrogated
220,233 unique compounds and identified 239 active compounds from which ten small molecules were further
characterized. Computation chemical cluster analyses indicated that six compounds were structurally related while the
remaining four compounds were classified as unrelated or singletons. All ten compounds were ,20-17,000-fold more
potent than lonidamine, a previously identified TbHK1 inhibitor. Seven compounds inhibited T. brucei blood stage form
parasite growth (0.03#EC50,3 mM) with parasite specificity of the compounds being demonstrated using insect stage T.
brucei parasites, Leishmania promastigotes, and mammalian cell lines. Analysis of two structurally related compounds,
ebselen and SID 17387000, revealed that both were mixed inhibitors of TbHK1 with respect to ATP. Additionally, both
compounds inhibited parasite lysate-derived HK activity. None of the compounds displayed structural similarity to known
hexokinase inhibitors or human African trypanosomiasis therapeutics.
Conclusions/Significance: The novel chemotypes identified here could represent leads for future therapeutic development
against the African trypanosome.
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Introduction
African sleeping sickness conjures historical images of disease-
induced fatal slumbering striking down men, women, and
children, consequently decimating villages of colonial Africa.
Unfortunately, people living in many countries of sub-Saharan
Africa today know that African sleeping sickness is not a disease of
history but rather is a much-neglected disease of the present,
particularly in areas that suffer the additional burdens of war,
famine, global and local climate changes, and other infectious
agents. The causative agents of sleeping sickness (or human
African trypanosomiasis, HAT) are subspecies of the African
trypanosome Trypanosoma brucei. Approximately 500,000 people in
sub-Saharan Africa are infected annually with the parasite leading
to 50,000–70,000 deaths per year [1]. Similar to other neglected
tropical diseases, limited therapeutics for HAT are available and of
the drugs currently used, most have serious adverse side effects,
including encephalopathy, toxicity, and death [2]. Thus, there is a
desperate need for new HAT therapeutics with the preference
shifting from general cytotoxic agents towards molecular target-
based therapeutics that should display fewer toxic effects.
Bloodstream form (BSF) T. brucei parasites generate ATP
exclusively through glycolysis and T. brucei hexokinase TbHK,
the first enzyme in glycolysis, has previously been validated as a
target for therapeutic development. In these experiments, BSF
parasites were shown to be sensitive to RNA interference (RNAi)-
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based silencing of TbHKs [3,4], with cell toxicity observed after 3–
5 days of RNAi exposure. Additonally, known inhibitors of HKs
have been demonstrated to inhibit T. brucei hexokinase 1
(TbHK1), one of two nearly identical TbHKs that the parasite
expresses. These compounds are furthermore toxic to the parasite
[4]. While some mammalian HK inhibitors can inhibit TbHK1,
TbHK1 is distinct enough from mammalian HKs to suggest that it
can be specifically targeted. Supporting this notion, TbHK1 shares
only 30–33% sequence identity with the mammalian HKs and
differs further by unusual oligomerization into hexamers [5].
Moreover, the unusual spectrum of known inhibitors of the
trypanosome enzymes, including fatty acids and other small
molecules (like pyrophosphate, [5]), support the idea that this
essential parasite protein is sufficiently distinct from any
mammalian counterpart to make an ideal target for therapeutic
development. Indeed, targeting TbHK using structurally based
inhibitors has yielded trypanocidal compounds, albeit at high
concentrations [6,7].
Here we describe our high throughput target-based approach to
identify specific inhibitors of the essential parasite enzyme,
TbHK1. Overall, ten compounds were confirmed as novel
TbHK1 small molecule inhibitors exhibiting little or no similarity
to known HK inhibitors (or HAT therapeutics). Most of the potent
TbHK1 inhibitors were toxic to culture-grown BSF T. brucei while
not exhibiting toxicity towards mammalian cells, suggesting that
they may be useful lead compounds in the development of new
therapies for African trypanosomiasis.
Methods
Chemicals and reagents
Clear 384-well microtiter plates were purchased from Greiner
(Monroe, NC) and used for all experiments. Glucose-6-phosphate
dehydrogenase, b-nicotinamide adenine dinucleotide (NAD+),
adenosine triphosphate (ATP), lipoic acid (PubChem SID
11532893) and glucose were purchased from Sigma (St. Louis,
MO). Phosphoenol pyruvate (PEP), ebselen (PubChem SID
856002) and glucosamine were obtained through VWR (West
Chester, PA) and dimethyl sulfoxide (DMSO) was purchased from
Fisher (Pittsburgh, PA). The following PubChem SID compounds
were obtained from commercial vendors: 3716597, 24830882,
17386310, and 16952891 (Enamine/Kiev, Ukraine); 24797131
(Chembridge/San Diego, CA); 14728414 and 17387000 (Specs/
Delft, The Netherlands); 17507245 (Asinex/Moscow, Russia); and
24785302 (ChemDiv, San Diego, CA).
Compound libraries
The library of pharmacologically active compounds (LOPAC)
(1,280 compounds) was purchased from Sigma-Aldrich. The
Pittsburgh Molecular Libraries Screening Center (PMLSC)
provided the 220,233 compound library screened for TbHK1
small molecule inhibitors, which was made available as part of the
NIH Molecular Libraries Roadmap Initiative. Cherry-picked
compounds from the PMLSC library were supplied by Biofo-
cusDPI (San Francisco, CA).
Purification of bacterially expressed TbHK1
For purification of bacterially expressed TbHK1 (rTbHK1), a
previously described protocol [8] was modified to increase yield.
Briefly, a starter culture of E. coli M15(pREP) harboring pQE30
(Qiagen, Valencia, CA) with the TbHK1 gene cloned in frame of
a 6-His tagging sequence was grown in ECPM1 [9] and then
inoculated into a 5 L bioreactor (Biostat B, B. Braun Biotech
International, Allentown, PA) and grown at 37uC. At OD600
between 3–5, the culture was induced with IPTG (0.8 mM), grown
without supplement O2 (37uC, 16 hr), and cells collected by
centrifugation (50006g, 20 min, 4uC). The pellet was resuspended
in lysis buffer (50 mM NaPO4, pH 8.1, 5 mM glucose, 150 mM
NaCl, and 0.1% Tween) and lysed by using a cell disruptor
(Constant Cell Disruption Systems, Sanford, NC). The resulting
supernatant was applied (5 ml/min) to a 50 ml ProBind column
(Invitrogen, Eugene, OR) on a FPLC (GE Lifesciences, Piscat-
away, NJ) and protein eluted by gradient (5 to 250 mM imidazole)
in lysis buffer. Fractions were screened using HK activity assays
and Western blotting and those containing rTbHK1 were pooled,
concentrated, and applied to a HiTrap SP HP column (GE
Lifesciences, Piscataway, NJ).
Automated primary TbHK1 HTS and glucose-6-phosphate
dehydrogenase coupled assays
TbHK1 assays were an adaptation of a coupled enzyme HK
assay to a 384-well format [8,10]. Briefly, test and control
compounds (30 mM in 15 mL volume) were added to a 384 well
black, opaque microtiter plate using a Velocity 11 V-prep (Santa
Clara, CA) for a final test compound concentration of 10 mM.
Negative (vehicle) controls contained 1% DMSO, positive controls
contained 133 mM glucosamine and IC50 controls contained
1.3 mM glucosamine (final well concentrations). A mixture
containing glucose (1.5 mM), ATP (1.05 mM), MgCl2 (4.5 mM),
NAD+ (9 mM), glucose-6-phosphate dehydrogenase (G6PDH,
0.018 mUnits/mL) and triethanolamine (TEA, 100 mM, pH 8.0)
in a 15 mL volume was then added to each well of the assay plate
using a Perkin Elmer FlexDrop (Waltham, MA) followed by
addition of rTbHK1 (1.5 ng/ml in 15 mL volume). The 45 mL
reaction mixture was incubated at RT for 2 hr and then quenched
with 5 mL EDTA (500 mM). The resulting signal, which remained
stable for up to 5 hr after addition of stop reagent, was collected on
a Molecular Devices SpectraMax M5 (absorbance at OD340)
(Sunnyvale, CA).
To account for possible inhibition of the reporter enzyme in the
primary coupled reaction, putative inhibitors were screened to
assess their activity against a G6PDH coupled assay. Briefly, test
and controls compounds were added to the wells of a 384 well
assay plates as described above. Negative (vehicle) controls
contained 1% DMSO, positive controls contained 100 mM PEP
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and IC50 controls contained 8.6 mM PEP (final well concentra-
tions). A mixture containing glucose-6-phosphate (G6P, 0.6 mM)
and NAD+ (1.8 mM) in a volume of 15 mL was then added to each
assay plate well. The reaction was initiated by addition of 15 mL
G6PDH (0.018 mUnits/mL) (for a final volume of 45 ml),
incubated at RT for 1 hr, and then quenched with 5 ml of EDTA
(500 mM). The change in absorbance at OD340 was monitored as
above.
Additional specificity assays were performed using human HK 4
(human glucokinase, hGlk, GenBank accession no. BC001890)
that was expressed from a cloned cDNA (OPEN Biosystems,
Huntsville, AL) in pQE30. After sequencing, the plasmid was
transformed into E. coli M15 (pREP) and cultures were grown to
an OD600 of 0.9 in terrific broth and protein expression induced
(3 hr, 37uC) with 1 mM IPTG followed by purification by nickel-
affinity chromatography.
Inhibition assays of lysate-derived TbHK
Parasite lysates from BSF parasites were prepared by incubation
(5 min on ice) of 1.56107 cells in lysis buffer (0.1 M TEA, pH 7.4,
and 0.1% Triton X-100) supplemented with 1 mM PMSF, 5 mg/
ml leupeptin, and 100 mg/ml TLCK. In triplicate, cell equivalents
(26105) were incubated with increasing concentrations of inhibitor
for 15 minutes at RT prior to initiation of the coupled reaction. In
short, the 200 ml reactions included 50 mM TEA, pH 7.4, 33 mM
MgCl2, 20 mM glucose, 5.25 mM ATP, 0.75 mM NADP, and 0.1
units of G6PDH, with kinetic analyses performed using Kaleida-
Graph 4.1 (Synergy Software, Reading, PA).
T. brucei viability assay
To determine the impact of TbHK1 inhibitors on cell growth,
we seeded 56103 BSF parasites (cell line 90–13, a 427 strain) into
96-well clear-bottomed polystyrene plates in 200 ml HMI-9
supplemented with 10% fetal bovine serum and 10% Serum Plus
(Sigma-Aldrich, St. Louis, MO) and grown in the presence of
compound (2 ml) or equivalently diluted carrier for 3 days in 5%
CO2 at 37uC. CellTiter Blue (Promega, Madison WI) was added
(20 ml) and the plates incubated an additional 3 hr under standard
culture conditions. Fluorescence emission at 585 nm was then
measured after excitation at 546 nm in a GENios microtiter plate
reader (Phenix Research Products, Hayward CA). DMSO solvent
was maintained at or below 1%, with 1% causing a 16% reduction
in cell number at the end of the three day assay.
Procyclic form (PF) parasites (29–13, a 427 strain, 56104/well)
were grown in 96-well clear-bottomed polystyrene plates in 200 ml
SDM-79 for 2 days (5% CO2, 25uC) and then CellTiter Blue (20 ml)
added. Plates were then incubated for 1 hr under standard culture
conditions. Fluorescence of samples was then characterized as above.
Mammalian cell-line and Leishmania promastigote
specificity assays
Cell-based specificity assays were performed as previously
described [11]. Briefly, mammalian cell line and Leishmania
promastigote assays were performed in final volumes of 25 mL
using our previously described 384-well microtiter format [12]. All
mammalian cell lines were cultured and maintained in complete
growth medium preparations according to ATCC specifications
(ATCC, Manassas, VA). Leishmania promastigotes were cultured as
previously described [11]. A549 (1,000 cells/22 mL), IMR-90
(1,000 cells/22 mL), HeLa (1,000 cells/22 mL), MDA-MB-231
(3,000 cells/22 mL), Leishmania promastigotes (5,000 parasites/
22 mL) were seeded into each well of 384-well microtiter plates
and test and control compounds (3 ml) were added to individual
wells. Vehicle and positive controls were 1% and 10% DMSO,
respectively. For mammalian cells, assay plates were incubated for
44–46 h at 37uC in the presence of 5% CO2 and for the Leishmania
promastigotes, assay plates were incubated for 44 h at 28uC with
5% CO2. Five mL of CellTiter Blue reagent was added to each
assay plate well and incubated for 2–4 h at 37uC with 5% CO2.
Data were captured on a Molecular Devices SpectraMax M5
(excitation A560; emission A590).
HTS data analysis and statistical analysis
Primary HTS data analysis and subsequent compound IC50
calculations were performed using ActivityBase (IDBS, Guilford,
UK) and Cytominer (University of Pittsburgh Drug Discovery
Institute, Pittsburgh, PA). Structural similarity of the confirmed
inhibitors was determined using Leadscope software (Columbus,
OH). Additional visualization and statistical analysis were
performed using GraphPad Prism software 5.0 and Spotfire
(Somerville, MA). The PubChem database (http://PubChem.
ncbi.nim.nih.gov) was used to verify if the confirmed TbHK1
small molecule inhibitors exhibited bioactivity in other assays.
In silico ADME/toxicity analysis
Computational modeling tools were used to estimate the
bioavailability, aqueous solubility, blood brain barrier potential,
human intestinal absorption, the cytochrome P450 (i.e. CYP2D6)
enzyme inhibition potential, mutagenicity, and hERG inhibition of
the confirmed TbHK1 inhibitors. The bioavailability, aqueous
solubility, and human intestinal absorption were estimated using the
ADME Boxes v4.0 software (Pharma Algorithms, Toronto, Canada),
while mutagenicity and hERG inhibition were estimated with TOX
Boxes v2.9 software (Pharma Algorithms, Toronto, Canada). The
CYP2D6 inhibition and blood brain barrier potential were predicted
using Accord for Excel 6.2.2 (Accelrys, Inc, San Diego).
Results
Validation of optimized HTS assay conditions using the
LOPAC set
The TbHK1 coupled assay was optimized and validated for
HTS by screening the LOPAC set. Compounds were assayed in
duplicate at a single concentration (10 mM) and reproducibility
between the duplicate screens is represented in Fig. 1 (R2 = 0.96).
Figure 1. Validation of the HTS by LOPAC screening. Plot of
percent inhibition for duplicate screen of the 1280 LOPAC compounds.
LOPAC compounds (blue), minimum control, which should equal
,100% inhibition of signal readout (red), IC50 control compounds
(yellow), and maximum control compounds, which should equal ,0%
inhibition of signal readout (green), are indicated.
doi:10.1371/journal.pntd.0000659.g001
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Average Z-factors were 0.6960.02 for the two LOPAC assays
demonstrating the robustness of the developed assay format [13].
Eighteen compounds inhibited TbHK1 enzymatic activity $40%
at 10 mM including myricetin, a structural analog of quercetin,
which was previously identified as a TbHK1 small molecule
inhibitor (IC50 =,85 mM) (Lyda and Morris, unpublished). These
data confirmed that our automated HTS assay conditions were
robust and could be used to identify compounds that inhibited
TbHK1 activity.
Interrogation of 220,233 compounds for TbHK1 small
molecule inhibitors
We next screened 220,223 compounds at a single concentration
(10 mM) for small molecule inhibitors of TbHK1 (Fig. 2). The
HTS assay performed robustly (average Z-factors of 0.8060.1)
and identified 239 compounds as primary actives (.50%
inhibition at 10 mM), for an overall hit rate of 0.1%. The 239
active compounds were cherry-picked, and the initial inhibitory
activity confirmed in the primary TbHK1 assay. Additionally, the
compounds were tested against the reporter enzyme, G6PDH, to
confirm that they did not interfere with the assay format.
Following initial 20 point IC50 value determinations using
cherrypicked compounds, compounds with IC50 values ,50 mM
were obtained from commercial sources. The activity of the 13
resupplied compounds was empirically determined to control for
possible TbHK1 inhibitory effects associated with compound
library degradation. Ten small molecules confirmed with TbHK1
IC50 values ,50 mM while three compounds failed to inhibit
TbHK1. Leadscope analysis of the 10 confirmed TbHK1
inhibitors classified six compounds into a cluster of structurally
related compounds (cluster 1) while the remaining four com-
pounds were classified as singletons (Table 1, Fig. 3). Ebselen (SID
856002) was the most potent compound in cluster 1 with an
IC50 = 0.0560.03 mM. For the majority of the compounds IC50
values either improved or remained similar to cherry-picked
compounds with the exceptions of SID 17386310 and SID
14728414 (Table 1) which were 7.5 and 6.6-fold less potent,
respectively, upon resupply (data not shown). Moreover, all ten
novel TbHK1 inhibitors were 20-17,000-fold more potent than
londiamine, a previously described TbHK1 inhibitor [4] and 2-
1720-fold more potent than quercetin (Lyda and Morris,
unpublished).
Additional experiments to assess the in vitro specificity included
testing the compounds against hGlk. The activity against hGlck
was varied, with the cluster 1 compounds yielding a spectrum of
efficacy, from very low inhibition at 10 mM (for example, SID
17387000, with 6.7% inhibition, Table 1) to near complete
inhibition by ebselen (97.8% inhibition). Singletons also demon-
strated a spectrum of activity against hGlck with SID 22401406
and SID 14728414 having minimal impact on the enzyme while
17386310 was a more potent inhibitor (Table 1). Moreover, data
mining of the PubChem database (http://pubchem.ncbi.nlm.nih.
gov/) determined the frequency with which a compound was
found to be active in other assays. In general, the cluster 1
compounds were active in other assays more frequently than the
singletons, with SID 17387000 the most frequently active
(identified in 7.2% of the 238 assays in which it was tested).
Figure 2. Scheme depicting HTS interrogation of a 220,233
small molecule library for TbHK1 inhibitors.
doi:10.1371/journal.pntd.0000659.g002
Table 1. HTS Cluster 1 and Singleton hits.
Leadscope
Grouping
PubChem
SID
PubChem
Bioassay Activity1
IC50 (mM)
Resupply
% Inhibition of
hGlck (10 mM) BSF EC50 (mM)
% PF Growth
Inhibition (10 mM)
L. major
EC50 (mM)
Cluster 1 856002
(Ebselen)
344/44/22 0.0560.03 97.860.1 2.960.28 5160.16 4.160.4
17387000 236/38/17 2.060.5 6.769.4 0.03060.067 4860.15 1.960.2
24785302 170/21/11 4.261.0 6.964.2 0.04260.0028 4760.15 1.960.2
3716597 318/29/18 9.360.3 7.867.1 .10 2760.080 .12.5
24830882 171/12/7 16.960.1 88.864.9 0.8360.20 8.660.030 .12.5
16952891 214/24/11 2.660.2 44.969.9 0.3060.079 4760.15 .12.5
Singletons 22401406 184/5/2 2.360.3 0.0 .10 0.0 .12.5
24797131 175/6/2 11.463.2 6.368.8 .10 0.0 .12.5
17386310 211/10/4 33.6610.2 70.363.6 0.03860.0038 5060.15 2.660.1
14728414 216/2/1 41.763.0 1.967.0 .10 0.0 .12.5
1As of 09/03/09. Number of bioassays in which the compound was tested/number in which the compound was active/number in which the compound has been
confirmed as an inhibitor.
doi:10.1371/journal.pntd.0000659.t001
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Singletons, on the other hand, were less frequently active. For
example, SID 14728414 was confirmed as an active in one of 216
assays (,1%) (Table 1).
TbHK1 small molecule inhibitors are toxic to BSF
parasites
TbHK1 has previously been shown to be an essential gene for
BSF T. brucei [4], suggesting that inhibitors of the enzyme may be
promising lead compounds for therapeutic development. To
initially explore this possibility, we grew cultured BSF parasites
in the presence of 10 mM compound and cell density monitored
after 72 hr (Table 1). The ten resupplied compounds were tested
in this assay, with EC50s determined for those that inhibited cell
growth .50% at 10 mM (Table 1). Compounds in cluster 1
included two of the most potent anti-trypanosomal compounds,
SID 17387000 and SID 24785302. Singletons were also toxic,
with SID 17386310 being one of the most potent compounds
tested to date. Four molecules, including a member of cluster 1
(SID 3716597) and three singletons (SID 22401406, SID
24797131, SID 14728414) inhibited TbHK1 but were not toxic
to BSF at 10 mM. With the exception of ebselen, the resupplied
anti-parasitic compounds exhibited EC50 values that were 10–
1000 fold lower than the TbHK1 IC50 values. This discrepancy
could result from other actions or concentration of the inhibitors in
the glycosome, which is a small peroxisome-like organelle where
TbHK1 is located. Additionally, we have found that RNAi of
TbHK1, which reduces expression but does not necessarily ablate
it, is toxic to BSF parasites, suggesting that modest inhibition of
cellular TbHK1 activity could be lethal to the parasite [4].
To explore the likelihood of off-target whole parasite effects, we
assessed the toxicity of the TbHK1 inhibitors against PF parasites.
Unlike BSF parasites, PF parasites can utilize both amino acids
and glucose for ATP production. This dynamic metabolism
suggests that the PF parasites may be less sensitive to TbHK1
inhibitors. Indeed, at 10 mM most of the resupplied compounds
had only a modest impact on PF parasite growth, inhibiting
growth between 0–51% when compared to control cell lines.
Compounds toxic to T. brucei were also assayed against a related
kinetoplastid parasite, Leishmania. The Leishmania promastigotes
were typically less sensitive to the resupplied compounds (with
EC50s .12.5 mM), with the exception of the cluster 1 compounds
ebselen, SID 17387000, SID 24785302 and the singleton, SID
17386310. These compounds had EC50 values against Leishmania
between 1–5 mM in exponentially growing parasites (Table 1).
Moreover, our identified TbHK1 inhibitors have minimal impact
on human cell lines with EC50 values .12.5 mM, suggesting at
least 400-fold greater toxicity toward parasites for the most potent
T. brucei cytotoxic compounds (Table 1).
In silico predictions for the identified TbHK1 inhibitors
To investigate the chemical similarity of our newly identified
TbHK1 small molecule inhibitors to current treatments for
African sleeping sickness as well as previously described TbHK1
inhibitors, we performed a similarity search using the Tanimoto
coefficient. The data indicated that the TbHK1 inhibitors
displayed low levels of similarity with all compounds examined
with the highest similarity being between lonidamine and SID
16952891 (47%) (Table 2). Thus, these results demonstrate that
the newly identified TbHK1 inhibitors are unique, either
displaying no or very low similarity to known TbHK1 inhibitors
and current therapies for African sleeping sickness.
Additional in silico ADME-tox predictions indicated that all ten
TbHK1 compounds had an extremely low probability for being
either a hERG channel inhibitor or mutagenic (data not shown).
Moreover, all compounds, except SID 3716597 were predicted to
Figure 3. Structures of the cluster 1 and singleton HTS hits.
doi:10.1371/journal.pntd.0000659.g003
Table 2. Comparison of structural similarities of HTS hits to licensed compounds used against HAT and to known TbHK1
inhibitors.
Compound Proposed Mode of Antiparasitic Action1 TbHK1 Inhibitor (SID) Similarity Coefficient2(%)
Pentamidine Accumulation in the mitochondria, DNA binding 17386310 31
Suramin Inhibition of glycolysis 24830882 38
24797131 38
Melarsoprol Inhibition of glycolysis Interaction with thiols 24830882 43
Eflornithine Polyamine biosynthesis (via inhibition of ODC) 14728414 27
Lonidamine TbHK1 inhibitor3 16952891 47
Quercetin TbHK1 inhibitor4 24797131 38
1Reviewed in [13].
2Similarity coefficient was determined using the Tanimoto coefficient. Compounds with values greater than 80% are considered highly structurally similar.
3[4].
4Lyda and Morris, unpublished.
doi:10.1371/journal.pntd.0000659.t002
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be moderately to highly bioavailable and nine of 10 compounds
displayed medium to very high blood brain barrier (BBB)
potential, with the majority of the cluster one compounds
predicted to have high to very high BBB potential (Table 3). Six
of 10 TbHK1 inhibitors were predicted to have no inhibitory
activity on CYP2D6 enzyme with the exceptions being cluster one
compounds SID 3716597 and SID 24785301 and singletons SID
14728414 and SID 24797131 (Table 3). The majority of the
compounds had a predicted low aqueous solubility (Table 3),
suggesting that if these compounds were to be used in future
analogue development, they would need to be refined to improve
their aqueous solubility. Thus, based on empirically derived data
and in silico analyses, we focused on cluster 1 compounds for
subsequent analyses.
Further characterization of two structurally related
cluster 1 TbHK1 small molecule inhibitors
Ebselen, 2-phenyl-1,2-benzisoselenazol-3(2H)-one, was the
most potent TbHK1 inhibitor (IC50 = 0.0560.03 mM) identified
in our studies while the structurally related inhibitor SID
17387000 (2-phenyl-1,2-benzisothiazol-3(2H)-one) was the next
potent compound identified with an IC50 = 2.060.5 mM
(Table 1). Analysis of the nature of TbHK1 inhibition revealed
that both ebselen and SID 17387000 were mixed inhibitors with
respect to ATP, with Ki values of 6.13 mM and 6.89 mM,
respectively (Fig. 4). However, both ebselen and SID 17387000
exhibited comparable IC50 values against T. brucei lysate-derived
TbHK1 enzymatic activity with IC50 values of 0.4360.02 mM
and 1.260.12 mM respectively (Fig. 5). Thus, while compound
SID 17387000 was nearly as potent against lysate activity as the
bacterially expressed protein, ebselen was significantly less potent
against parasite lysate-derived TbHK1 activity (than the
bacterially expressed protein). These results suggest that ebselen
may be metabolized by cellular components or that lysate-derived
TbHK1 may be associated with various cofactors that result in
less potent IC50 values. Ebselen was also a potent inhibitor of
hGlck (97.8% inhibition at 10 mM), while SID 17387000 had
relatively little activity (6.7% inhibition) against the kinase
(Table 1). Moreover, ebselen was ,100-fold less active against
BSF parasites (Table 1). Taken together, these data suggest that
the subtle structural differences between the two compounds
result in remarkable changes in their pharmacological behavior.
Both ebselen and SID 17387000 are potent trypanocides, with
EC50s of 2.960.28 mM and 0.03060.067 mM, respectively. To
determine if indeed the toxicity to BSF parasites is related to
inhibition of cellular TbHK1, we measured the impact of the
compounds on cellular G6P levels after culturing the parasites in
the presence of ebselen and SID 17387000 [14] (Fig. 5C). To
reduce the likelihood that toxicity was impacting G6P levels non-
specifically, we limited the incubation period to 1 and 4 hours,
while employing high doses (10 times the EC50) of the compounds.
Incubation with ebselen for either 1 or 4 hours led to a 56% or
70% reduction in G6P, while SID 17387000 was less effective,
reducing G6P levels 29% and 18% after 1 and 4 hours,
respectively (Fig. 5C). While these observations suggest a direct
impact on TbHK activity, other off-target impacts could be
ultimately responsible for toxicity.
Table 3. In silico ADME/toxicity analysis.
Leadscope
Grouping PubChem SID Aqueous Solubility Bioavailability CYP2D6 inhibition Blood brain barrier
Cluster 1 856002 (Ebselen) Low High Non-inhibitor High
17387000 Low High Non-inhibitor High
24785302 Low Moderate Inhibitor Very High
3716597 Low Low Inhibitor Medium
24830882 Good High Non-inhibitor High
16952891 Low Moderate Non-inhibitor Medium
Singletons 22401406 Extremely Low Moderate Non-inhibitor Undefined
24797131 Good High Inhibitor Medium
17386310 Good Moderate Non-inhibitor Medium
14728414 Low Moderate Inhibitor High
doi:10.1371/journal.pntd.0000659.t003
Figure 4. Ebselen and SID 17387000 are mixed inhibitors of
TbHK1 with respect to ATP. Lineweaver-Burk plots of inhibition with
ebselen (A.) or SID 17387000 (B.). Assays were performed as described
for cell lystates (see Materials and Methods) with ATP concentrations
varied.
doi:10.1371/journal.pntd.0000659.g004
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Discussion
There are currently four drugs approved for treatment of HAT.
However, suramin and pentamidine, developed in 1921 and 1941,
respectively, are not effective against the late stage of disease that
occurs when the parasite crosses the blood-brain barrier.
Melarsoprol, which was introduced in 1949, leads to fatal
complications in 5–10% of patients receiving the drug [15]. The
most recently developed drug, eflornithine, is only efficacious
against T. b. gambiense, but is curative for both the early blood-
borne infection and the late stage of disease with central nervous
system involvement; delivery of eflornithine is difficult, as the
compound must be administered intravenously four times a day
for 14 days (delivering ,360 g/patient).
A number of screens of chemical libraries have been
undertaken to identify therapeutic leads against the African
trypanosome. These include a phenotypic screen that interrogat-
ed a library of FDA-approved drugs for anti-trypanosomal
activity [16], as well as screens developed to identify inhibitors
of essential parasite enzymes. A screen for UDP-Glc 49-epimerase
inhibitors using a small natural products library [17] and a screen
of a commercial 134,500 compound library for trypanothione
reductase inhibitors [18] are two examples of target-based screens
used to identify lead compounds for therapeutic development. In
the last few years, TbHK inhibitors have been explored as
potential anti-parasitic compounds. Previous efforts to identify
TbHK inhibitors include the development of compounds based
on models of the TbHK structure (predicted from homology
studies of the yeast structure), and exploring the activity of HK
inhibitors from other systems [4]. Here we have used a HTS of
220,223 compounds to identify new inhibitors of the parasite
enzyme.
In our screens, we have identified several novel inhibitors of
TbHK1. One compound, ebselen, was the most potent inhibitor
from both the LOPAC validation screen and the HTS. Ebselen is
a lipid-soluble seleno-organic compound that has been employed
in clinical trials to assess its value in prevention of ischemic
damage in brain hemorrhage and stroke [19,20]. Ebselen inhibits
lipid peroxidation through a glutathione peroxidase-like action
[21], but may act through other mechanisms as well. Notably, a
single oral dose (100 mg/kg) of ebselen yields serum values of 4–
5 mM [22] and brain levels of the drug reach 21% of plasma
levels [23], suggesting that the compound (or its derivatives) may
be useful for both early and late stage sleeping sickness therapy
development.
Ebselen likely has polypharmacological effects on BSF parasites,
as the compound is known to inhibit a number of enzymes in
addition to TbHK1, including the trypanosome UDP-Glc 49-
epimerase [17]. Ebselen, unlike other cluster 1 compounds, has an
IC50 that is significantly lower than the EC50, suggesting its
metabolism may be distinct from the sulfur-bearing compounds.
Alternatively, a cellular ‘‘sink’’ could be interacting with ebselen,
thereby lowering its effective concentration.
The remaining cluster 1 compounds have EC50s notably lower
than their TbHK1 IC50s, suggesting possible actions on other
cellular targets. Alternatively, differences between the two values
could result from the concentration of the compound within the
parasite (perhaps in the glycosome) or metabolism of the inhibitor
to a more potent form. These hypotheses would seem worthy of
further investigation.
An ideal therapeutic drug for African sleeping sickness would
target the parasite (while perhaps enhancing host immune
responses) and work at concentrations low enough to limit the
severity of side effects. In the search for potential drug targets, we
have focused on the trypanosome TbHK1, a protein that the
parasite requires to make ATP and have identified compounds
that may serve as leads in for the development of therapeutics in
the continuing fight against the African trypanosome.
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Figure 5. Ebselen and SID 17387000 inhibit TbHK activity from
parasite cell lysate and cause a reduction in cellular G6P levels
in BSF parasites. Increasing amounts of (A.) ebselen or (B.) SID
17387000 were incubated with 26105 BSF cell equivalents for 15 min at
RT and HK assays were performed as described in the Materials and
Methods. (C.) Growth in the presence of Ebselen or SID 17387000
causes a reduction in cellular G6P levels. BSF parasites (16107) were
cultured for 1 or 4 hours in the presence of 30 mM or 1 mM (10-fold the
EC50) ebselen or SID 17387000 followed by lysate preparation and
comparison of G6P levels to an equivalent number of untreated
parasites [14].
doi:10.1371/journal.pntd.0000659.g005
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